These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36526885)

  • 1. Power analysis for idiographic (within-subject) clinical trials: Implications for treatments of rare conditions and precision medicine.
    Tueller S; Ramirez D; Cance JD; Ye A; Wheeler AC; Fan Z; Hornik C; Ridenour TA
    Behav Res Methods; 2023 Dec; 55(8):4175-4199. PubMed ID: 36526885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data.
    Harden M; Friede T
    Biom J; 2020 Sep; 62(5):1284-1299. PubMed ID: 32128868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accounting for the rarity of the disease when designing clinical trials with a focus on pediatric cancers.
    Mauguen A
    Clin Trials; 2022 Jun; 19(3):292-296. PubMed ID: 35232288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical Trials Mosaic: Toward a Range of Clinical Trials Designs to Optimize Evidence-Based Treatment.
    Ridenour TA; Chen SK; Liu HY; Bobashev GV; Hill K; Cooper R
    J Pers Oriented Res; 2017; 3(1):28-48. PubMed ID: 33569122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Large a Study Is Needed to Detect TKA Revision Rate Reductions Attributable to Robotic or Navigated Technologies? A Simulation-based Power Analysis.
    Hickey MD; Anglin C; Masri B; Hodgson AJ
    Clin Orthop Relat Res; 2021 Nov; 479(11):2350-2361. PubMed ID: 34351313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Assessment Design and Statistical Power for Detecting an Intervention Impact.
    Petras H
    Prev Sci; 2016 Oct; 17(7):819-29. PubMed ID: 27106693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size and power calculations for medical studies by simulation when closed form expressions are not available.
    Landau S; Stahl D
    Stat Methods Med Res; 2013 Jun; 22(3):324-45. PubMed ID: 22491174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tests for inter-subject and total variabilities under crossover designs.
    Lee Y; Shao J; Chow SC; Wang H
    J Biopharm Stat; 2002 Nov; 12(4):503-34. PubMed ID: 12477072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplification or simulation: Power calculation in clinical trials.
    Huang C; Li P; Martin CR
    Contemp Clin Trials; 2022 Feb; 113():106663. PubMed ID: 34958933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Power analysis in a SMART design: sample size estimation for determining the best embedded dynamic treatment regime.
    Artman WJ; Nahum-Shani I; Wu T; Mckay JR; Ertefaie A
    Biostatistics; 2020 Jul; 21(3):432-448. PubMed ID: 30380020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of bias: a simulation study of power to detect study-level moderator effects in meta-analysis.
    Hempel S; Miles JN; Booth MJ; Wang Z; Morton SC; Shekelle PG
    Syst Rev; 2013 Nov; 2():107. PubMed ID: 24286208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model based design and analysis of phase II HIV-1 trials.
    Rekić D; Röshammar D; Simonsson US
    J Pharmacokinet Pharmacodyn; 2013 Aug; 40(4):487-96. PubMed ID: 23843051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting a Within- or Between-Subject Design for Mediation: Validity, Causality, and Statistical Power.
    Montoya AK
    Multivariate Behav Res; 2023; 58(3):616-636. PubMed ID: 35679239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical power in two-level models: A tutorial based on Monte Carlo simulation.
    Arend MG; Schäfer T
    Psychol Methods; 2019 Feb; 24(1):1-19. PubMed ID: 30265048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical power of latent growth curve models to detect quadratic growth.
    Diallo TM; Morin AJ; Parker PD
    Behav Res Methods; 2014 Jun; 46(2):357-71. PubMed ID: 24234337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.